Knowledge Management System of Hefei Institute of Physical Science,CAS
Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma | |
其他题名 | Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma |
2016-01-01 | |
发表期刊 | CHINESE JOURNAL OF CANCER |
ISSN | 1000-467X |
摘要 | Background: Salvage treatment for locally recurrent nasopharyngeal carcinoma (NPC) is complicated and relatively limited. Radiotherapy, combined with effective concomitant chemotherapy, may improve clinical treatment outcomes. We conducted a phase II randomized controlled trial to evaluate the efficacy of intensity-modulated radiotherapy with concomitant weekly cisplatin on locally recurrent NPC. |
其他摘要 | Background Salvage treatment for locally recurrent nasopharyngeal carcinoma (NPC) is complicated and relatively limited. Radiotherapy, combined with effective concomitant chemotherapy, may improve clinical treatment outcomes. We conducted a phase II randomized controlled trial to evaluate the efficacy of intensity-modulated radiotherapy with concomitant weekly cisplatin on locally recurrent NPC. Methods Between April 2002 and January 2008, 69 patients diagnosed with non-metastatic locally recurrent NPC were randomly assigned to either concomitant chemoradiotherapy group ( n =34) or radiotherapy alone group ( n =35). All patients received intensity-modulated radiotherapy. The radiotherapy dose for both groups was 60Gy in 27 fractions for 37days (range 23–53days). The concomitant chemotherapy schedule was cisplatin 30mg 2 by intravenous infusion weekly during radiotherapy. Results The median follow-up period of all patients was 35months (range 2–112months). Between concomitant chemoradiotherapy and radiotherapy groups, there was only significant difference in the 3-year and 5-year overall survival (OS) rates (68.7% vs. 42.2%, P =0.016 and 41.8% vs. 27.5%, P =0.049, respectively). Subgroup analysis showed that concomitant chemoradiotherapy significantly improved the 5-year OS rate especially for patients in stage rT3–4 (33.0% vs. 13.2%, P =0.009), stages III–IV (34.3% vs. 13.2%, P =0.006), recurrence interval >30months (49.0% vs. 20.6%, P =0.017), and tumor volume >26cm 3 (37.6% vs. 0%, P =0.006). Conclusion Compared with radiotherapy alone, concomitant chemoradiotherapy can improve OS of the patients with locally recurrent NPC, especially those with advanced T category (rT3–4) and stage (III–IV) diseases, recurrence intervals >30months, and tumor volume >26cm 3 . |
关键词 | CONCURRENT CHEMORADIOTHERAPY PROGNOSTIC-FACTORS RADIATION-THERAPY NECK-CANCER REIRRADIATION CHEMOTHERAPY SURVIVAL METAANALYSIS RETREATMENT HEAD Recurrence Nasopharyngeal carcinoma Intensity-modulated radiation therapy Concomitant chemoradiotherapy Cisplatin |
收录类别 | CSCD |
语种 | 英语 |
CSCD记录号 | CSCD:5690104 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.hfcas.ac.cn:8080/handle/334002/61847 |
专题 | 中国科学院合肥物质科学研究院 |
推荐引用方式 GB/T 7714 | . Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma[J]. CHINESE JOURNAL OF CANCER,2016,35. |
APA | (2016).Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma.CHINESE JOURNAL OF CANCER,35. |
MLA | "Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma".CHINESE JOURNAL OF CANCER 35(2016). |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
推荐该条目 |
保存到收藏夹 |
查看访问统计 |
导出为Endnote文件 |
谷歌学术 |
谷歌学术中相似的文章 |
百度学术 |
百度学术中相似的文章 |
必应学术 |
必应学术中相似的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论